Luciferase expression provides the molecular link between tumor cells and the optical readout. Once the substrate, such as luciferin, is administered, luciferase catalyzes a light-producing reaction. The resulting photons travel through surrounding tissue and are captured by a sensitive camera, allowing researchers to associate detected signal with engineered cancer cells.
Changes in signal intensity can serve as a longitudinal indicator of tumor behavior. An increasing or decreasing signal may correspond to changes in tumor burden, while the location or spread of signal can provide information about distribution. Repeated measurements therefore help track progression or treatment response without requiring tissue collection at every time point.
Engineering supplies the enzyme required for the light-producing reaction, creating a measurable connection between labeled cancer cells and the camera signal. Without luciferase expression in the tumor cells, administration of the substrate would not produce the same cell-associated optical readout. This design enables researchers to follow those cells during experiments.
Researchers first establish tumor cells that express luciferase in a living experimental model. They then administer the appropriate substrate, such as luciferin, and use a sensitive camera to detect emitted photons through surrounding tissue. Repeating this sequence over time produces measurements that can be compared across tumor progression or treatment studies.
The approach permits noninvasive observation of cancer-related changes in living experimental models, reducing the need for repeated tissue collection. Because measurements can be obtained over time, researchers can follow tumor progression, metastatic distribution, and response to therapy. This supports longitudinal assessment of therapeutic efficacy while preserving the model for subsequent observations.
Researchers can compare bioluminescent measurements over time to assess whether tumor-associated signal changes after treatment. A change in intensity may indicate altered tumor burden, while a change in distribution may reflect altered spread. The method therefore provides a noninvasive readout for studying therapeutic efficacy alongside cancer progression and metastasis in preclinical models.